



**GRIFOLS**

FOR IMMEDIATE RELEASE

## **Cardinal Health and Grifols concluded an exclusive 6 year distribution agreement.**

**Rolle, Switzerland, April 23, 2008** — Cardinal Health, a global provider of products and services that improve the safety and productivity of healthcare, and Grifols, a Spanish holding company specialized in the pharmaceutical-hospital sector, have renewed their partnership and signed an exclusive six year distribution agreement. .

Under this agreement Grifols will continue to distribute and provide technical implementation services for Pyxis® automated medication and supply management product lines in Spain, Portugal and Latin America. The geographic scope is extended to Portuguese-speaking African countries. Thanks to their successful nine year partnership, Cardinal Health and Grifols have become leaders in the medication and supply automation market in Spain, Portugal and several countries in Latin America. More than seventy hospitals have adopted the Pyxis® automation solutions in those regions. The new agreement will further strengthen the partnership and collaboration between the two companies.

Mrs. Jean van Soelen, VP Marketing Pyxis International of Cardinal Health, said “The partnership will enable new solution offerings for our Spanish and Portuguese speaking customers. Grifols has tremendous customer satisfaction in the markets they have chosen to serve. The intimacy of their customer relationships will provide Cardinal Health market data to fuel innovation on the next generation of Pyxis® automation technology and better serve our Latin customers.”

Mr. Ramon Riera, VP Marketing and Sales at Grifols agreed that this association has brought benefits to his company. “Since 1999 we have gained expertise in automating logistic processes in hospitals, becoming the partner of choice in the markets where we are cooperating with Cardinal Health selling Pyxis. This partnership with the global leader in automating dispensing systems means that Grifols will continue its strategy of incorporating top level quality products to our current portfolio, offering our customers cutting edge solutions to satisfy their current and future needs.”

With this extended partnership both parties will leverage on prior successes in order to further penetrate the healthcare technology market in Latin America and Africa.



**GRIFOLS**

**About Cardinal Health**

Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is an \$87 billion, global company serving the health-care industry with products and services that help hospitals, physician offices and pharmacies reduce costs, improve safety, productivity and profitability, and deliver better care to patients. With a focus on making supply chains more efficient, reducing hospital-acquired infections and breaking the cycle of harmful medication errors, Cardinal Health develops market-leading technologies, including Alaris® IV pumps, Pyxis® automated dispensing systems, MedMined™ electronic infection surveillance service, VIASYS® respiratory care products and the CareFusion™ patient identification system. The company also manufactures medical and surgical products and is one of the largest distributors of pharmaceuticals and medical supplies worldwide. Ranked No. 19 on the Fortune 500, Cardinal Health employs more than 40,000 people on five continents. More information about the company may be found at [www.cardinalhealth.com](http://www.cardinalhealth.com)

**About Grifols**

Grifols is a Spanish holding company specializing in the pharmaceutical- hospital industry, with a presence in more than 90 countries. Since May of 2006 their share have been traded on the Spanish Stock Exchange (Mercado Continuo Español) and was included in the Spanish index IBEX 35 effectively since January 2008. It is currently the leading European company in the plasma therapies industry and the fourth-largest producer in the world. In the coming years, Grifols will leverage its market leadership as a vertically integrated company through past and future investments that will allow it to ensure its plasma supply through 77 plasmapheresis centers located in the United States, while at the same time expanding fractionating capacity with production facilities in Barcelona and Los Angeles, capable of meeting the growing market demand. More information about Grifols can be found at [www.grifols.com](http://www.grifols.com) .